Details

Autor(en) / Beteiligte

• Kivelä, Tero T
• Piperno-Neumann, Sophie
• Desjardins, Laurence
• Schmittel, Alexander
• Bechrakis, Nikolaos
• Midena, Edoardo
• Leyvraz, Serge
• Zografos, Leonidas
• Grange, Jean-Daniel
• Ract-Madoux, Guillaume
• Marshall, Ernest
• Damato, Bertil
• Eskelin, Sebastian

Titel

Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group

Ist Teil von

• American journal of ophthalmology, 2016-08, Vol.168, p.217-226

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Purpose To validate a staging system for metastatic uveal melanoma that will facilitate planning, reporting and interpreting the results of clinical trials. Design Reliability and validity study. Methods The performance index, the largest diameter of the largest metastasis and alkaline phosphatase level at the time of diagnosis of metastases, and overall survival of 249 patients from 7 ocular oncology centers who died of dissemination were analyzed. Predicted median survival time calculated according to the Helsinki University Hospital Working Formulation was used to assign patients to stages IVa, IVb, and IVc that correspond to predicted survival times of ≥12, <12-6, and <6 months, respectively. The predictions were compared against observed survival. Results The three variables used to assign stage were independent predictors of survival in the validation dataset. Of the 249 patients, 44%, 44%, and 12% classified to Working Formulation stages IVa, IVb, and IVc, respectively. Corresponding median observed survival times were 18.6, 10.7 and 4.6 months and worsened by increasing stage ( P <. 001). Of 201 patients managed without surgical resection of metastases, 41%, 44%, and 15% classified to stages IVa to IVc, and their median observed survival times were 17.2, 10.0 and 4.6 months ( P < .001). Survival of 47 patients who underwent resection did not differ by working formulation stage ( P = .69). Conclusions This multicenter study confirms that the Working Formulation is a reliable and valid, repeatable system for dividing metastatic uveal melanoma into distinct prognostic subgroups, especially for stage-specific reporting of survival in prospective clinical trials.